Allens has a wide range of lawyers and support staff who can assist with media queries and articles. For more information, please contact Public Relations and Social Media Manager Katie Szittner on +61 2 9230 5459 or email Katie.Szittner@allens.com.au or Senior Corporate Communications Manager Germaine Graham on +61 2 9230 4639 or email Germaine.Graham@allens.com.au.
You can also subscribe to receive our media releases by RSS feed.
Allens advises financiers on Icon Group acquisition - 25 May 2017
Allens has advised Credit Suisse AG and Goldman Sachs Australia as financiers of the acquisition of the Icon Group, Australia's largest private cancer and oncology services group.
Allens advises EBOS Group on acquisition of HPS - 23 May 2017
Allens has advised EBOS Group Limited on the proposed purchase of HPS, Australia's largest provider of outsourced pharmacy services.
Allens advises Healthe Care on two major acquisitions - 8 May 2017
Allens has advised leading Australian private hospital operator Healthe Care Australia in relation to the acquisition of ASX-listed Pulse Health Limited and three hospitals in the Illawarra region of New South Wales.
Dixon Hospitality says cheers to Beer DeLuxe - 22 August 2016
Allens has advised Dixon Hospitality on its acquisition of the Beer DeLuxe venues in NSW and Victoria.
Allens advises Archer Capital on sale of Healthe Care - 8 December 2015
Allens has advised Archer Capital on its proposed divestment of private hospital business Healthe Care to China's Luye Medical Group.
Allens advises Healthscope on sale of Australian pathology business - 23 June 2015
Allens has acted for one of Australia's leading private healthcare operators, Healthscope Limited, on the sale of its Australian pathology operations to Crescent Capital Partners for $105 million.
Allens lends a hand to Global Health - 16 March 2015
Allens has advised the Global Health Investment Fund (GHIF), a private investment fund whose mission is to finance late-stage drugs, vaccines and diagnostics for diseases that disproportionately burden low-income populations, on a US$10 million program with Medicines Development, a not-for-profit biopharmaceutical company headquartered in Melbourne.